![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-3.50 | -0.23% | 1,526.00 | 1,527.50 | 1,528.00 | 1,538.50 | 1,512.00 | 1,519.50 | 5,861,235 | 16:35:10 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 12.77 | 62.91B |
Date | Subject | Author | Discuss |
---|---|---|---|
01/5/2019 15:50 | If you have 40000 shares and you buy and sell some or all of them when the share price spikes either way then you could make a capital gains of £100,000,timing and luck will have to be your co-pilots . | abdullla | |
01/5/2019 14:58 | Dividend will never be increased been the same for years, just like holding a bond not a ord share. The whole point holding shares is for dividend growth and capital gain. GSK shareprice the same has it was 25 years ago, what growth. Poor show. | ![]() montyhedge | |
01/5/2019 13:52 | Just cannot seem to sort earning cash, earnings per share poor, always the same, hover around this until ex div then back to 15.20, time to buy in and sell again on way to next ex div, good trading share but thats all, useless for capital growth and if you want income there are funds with higher yields and lower stock specific risks, if she decides to buy another bio tech for billions this will tank again and put div at risk, its still being paid from debt. I know you " lifers " are waiting for the March to 1900 but its never gonna happen. | ![]() porsche1945 | |
01/5/2019 13:35 | Great figs imo! spud | spud | |
01/5/2019 13:28 | Thanks TM,you are right,euphoria was at the open for most investors when the share price jumped 20p at the opening bell,now things are balancing out for a brighter future,imo | abdullla | |
01/5/2019 12:49 | abdullla: The reduction primarily reflected the adverse phasing of payments for returns and rebates, as well as the initial step-down impact from Advair generic competition and an increase in trade receivables as a result of strong sales in the quarter, partly offset by improved operating profits and lower contingent consideration payments compared with Q1 2018 which included a milestone payment to Novartis. | tradermichael | |
01/5/2019 12:39 | There's those who are reading between the lines,abdullla just on the first paragraph hence the euphoria,sorry | abdullla | |
01/5/2019 12:35 | Market thinking too. ;) | ![]() alphorn | |
01/5/2019 12:32 | Make your mind up, abdulla. | ![]() keyno | |
01/5/2019 12:24 | Maybe issues short term, but the longer term is looking good, which I think is an improving picture! | jadeticl3 | |
01/5/2019 12:16 | Looks trouble ahead on free cash flow | abdullla | |
01/5/2019 12:09 | With these results she should be dishing out caviar. | abdullla | |
01/5/2019 08:52 | Yes, but Emma will be serving tea and biscuits during the webcast at 14.00 BST | tradermichael | |
01/5/2019 08:51 | They need to sort out their manufacturing problems ! | ![]() gbh2 | |
01/5/2019 08:36 | Yes you better have the tea trolley ready when the masters wake up. | abdullla | |
01/5/2019 08:35 | 12.00 GMT last year :-) | sicker | |
01/5/2019 07:50 | yes, but I think they wait until the US wakes up. | ![]() thamestrader | |
01/5/2019 07:49 | Are results due out today? | jadeticl3 | |
01/5/2019 07:05 | 2 weeks to next x-dividend …… ;0) | tradermichael | |
30/4/2019 21:10 | TM - will they all be additional sales or will some of those new sales come from existing drugs (sales)? | ![]() alphorn | |
30/4/2019 21:07 | Some of the world’s largest drugmakers painted an optimistic picture of the industry’s prospects this year, after posting better than expected first-quarter earnings thanks to growth in China and new cancer treatments. Pfizer, Merck and Eli Lilly all increased their earnings forecasts for 2019 on Tuesday, even as investors continue to worry about the prospect of US regulation on drug prices and US presidential candidates pledge to transform the healthcare system. Interesting comment vis earnings forecasts UP despite fear over US regulation on drug prices..... | ![]() crossing_the_rubicon | |
29/4/2019 18:23 | Not sure what you mean? | tradermichael | |
29/4/2019 14:01 | TM - will that be incremental sales or cannibalisation? | ![]() alphorn |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions